polycystic liverdisease
Conditions
Interventions
None listed
Sponsors
Universitair Medisch Centrum Sint Radboud
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: · 18 yrs-of age · Multiple cysts > 20 · Cooperating patient · Is willing and able to comply with the study drug regimen and all other study requirements. · Willingness to give written informed consent
Exclusion criteria
Exclusion criteria: · Use of oral anticonceptives or estrogen suppletion · Females who are pregnant or breast-feeding · History or other evidence of chronic pulmonary disease associated with functional limitation · History of severe cardiac disease (eg, NYHA Functional Class III or IV, myocardial infarction within 6 months, ventricular tachyarrhythmias requiring ongoing treatment, unstable angina or other significant cardiovascular diseases). In addition, patients with documented or presumed coronary artery disease or cerebrovascular disease should not be enrolled. · History or other evidence of severe illness or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study · Symptomatic gallstones (lanreotide decreases gall bladder volume) · Renal failure requiring hemodialysis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction of total liver volume as determined by multidetector CT scan (MDCT). | — |
Secondary
| Measure | Time frame |
|---|---|
| Reduction of liver volume and individual cyst volume on MDCT. Symptom evaluation by validated questionnaire | — |
Countries
Netherlands
Outcome results
None listed